
|Videos|March 1, 2016
Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 Pathway
Author(s)Arlene Sharpe, MD, PhD
Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Advertisement
Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the discovery of the PD-L1 pathway and the importance of the pathway in inhibiting anti-tumor immunity. Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Sharpe adds that the pathway was initially tested in both melanoma and lung cancer, which proved the pathway's usefulness in essentially all cancer types.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
4
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
5







































